vTv Therapeutics (NASDAQ:VTVT) Upgraded to Hold at Wall Street Zen

Key Points

• Wall Street Zen upgraded vTv Therapeutics from “Sell” to “Hold,” while the broader analyst consensus remains “Moderate Buy” with a $55.83 price target.
• VTVT shares opened at $30.57, versus a 52-week range of $19.50 to $44.00; the company has a market capitalization of approximately $120.4 million.
• The clinical-stage biotechnology company reported a quarterly loss of $1.05 per share, missing expectations by $0.08. Its lead candidate, TTP399, is being studied as an oral adjunct treatment for people with type 1 diabetes.

vTv Therapeutics (NASDAQ:VTVT - Get Free Report) was upgraded by research analysts at Wall Street Zen from a "sell" rating to a "hold" rating in a research note issued on Saturday, Wall Street Zen reports.

Other research analysts also recently issued research reports about the stock. Zacks Research upgraded shares of vTv Therapeutics from a "strong sell" rating to a "hold" rating in a research report on Monday, September 7th. Rodman & Renshaw started coverage on shares of vTv Therapeutics in a report on Tuesday, June 30th. They issued a "buy" rating and a $67.00 price target for the company. Lifesci Capital raised shares of vTv Therapeutics to a "strong-buy" rating in a research note on Wednesday, September 2nd. HC Wainwright dropped their price objective on shares of vTv Therapeutics from $45.00 to $42.00 and set a "buy" rating on the stock in a report on Thursday, August 6th. Finally, BTIG Research increased their price objective on shares of vTv Therapeutics from $49.00 to $57.00 and gave the stock a "buy" rating in a research report on Thursday, July 16th. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $55.83.

vTv Therapeutics Stock Performance

Shares of VTVT stock opened at $30.57 on Friday. The company has a market cap of $120.42 million, a P/E ratio of -28.84 and a beta of 0.21. The stock has a 50 day simple moving average of $32.14 and a two-hundred day simple moving average of $33.90. vTv Therapeutics has a fifty-two week low of $19.50 and a fifty-two week high of $44.00.

vTv Therapeutics (NASDAQ:VTVT - Get Free Report) last issued its quarterly earnings results on Thursday, August 6th. The biotechnology company reported ($1.05) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.97) by ($0.08). On average, research analysts predict that vTv Therapeutics will post -2.35 earnings per share for the current year.

vTv Therapeutics Company Profile

vTv Therapeutics is a clinical-stage biopharmaceutical company focused on developing orally administered small-molecule therapies for metabolic and inflammatory diseases. The company's research programs are based on its proprietary drug-discovery platform and are intended to address conditions for which additional treatment options are needed.

Its lead product candidate is TTP399, an oral, liver-selective glucokinase activator being studied as an adjunct to insulin for people with type 1 diabetes.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.